The ESR1 Knockout Raji Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte cell line, in which the gene encoding estrogen receptor alpha (ESR1) has been disrupted. This pooled knockout model is designed for loss-of-function studies investigating the role of ESR1 in B cell biology and estrogen-responsive signaling. The polyclonal format provides a heterogeneous knockout population, avoiding clonal biases while preserving the overall genetic disruption. This product is suitable for applications requiring a mixed knockout background rather than a single clonal isolate, and it should be validated by the end user for specific experimental contexts such as gene expression analysis or signaling perturbations.
The Raji cell line originates from a Burkitt lymphoma patient and represents a well-established model of human B lymphocytes. These cells exhibit characteristics of mature B cells and are widely employed in immunology, virology, and cancer research due to their robust growth and expression of B cell markers. Raji cells are instrumental in studies of antibody production, adaptive immunity, and lymphomagenesis. Their derivation from a B cell malignancy also makes them a relevant system for exploring the intersection of oncogenic signaling and immune cell function, particularly in the context of hormone-dependent pathways that may influence lymphoma biology.
ESR1 encodes a ligand-activated transcription factor that mediates the genomic effects of estrogen. Upon binding estradiol, ESR1 dimerizes, translocates to the nucleus, and regulates the expression of target genes such as TFF1, GREB1, PGR, MYC, CCND1, and BCL2 that control cell proliferation, survival, and differentiation. Its activity is modulated by upstream signals including EGF, IGF-1, MAPK, AKT, and PKA, and it interacts with coactivators like NCOA1 and NCOA2 or corepressors NCOR1 and NCOR2, along with transcription factors SP1 and AP-1. In addition to classical transcriptional regulation, ESR1 triggers rapid non-genomic signaling cascades, notably the MAPK/ERK and PI3K/AKT pathways, which further integrate estrogen inputs with broader cellular responses.
In Raji B lymphocytes, disruption of ESR1 enables dissection of estrogen receptor function in an immune cell context where its role is less defined than in reproductive tissues. This knockout model is valuable for studying how estrogen signaling influences B cell proliferation, survival, and lymphoma progression, potentially mediated via crosstalk with pathways such as NF-??B and Notch. The loss of ESR1 may affect the expression of downstream targets and alter sensitivity to hormone-dependent stimuli, offering a platform to evaluate anti-estrogen therapies in hematological malignancies. Moreover, it facilitates exploration of estrogen??s immunomodulatory effects in autoimmune diseases where B cells are key effectors.
Typical applications include Western blotting and RT-qPCR to confirm knockout efficiency and monitor transcript changes, RNA-seq for global expression profiling, ChIP-qPCR to assess ESR1 chromatin occupancy, immunofluorescence and flow cytometry for protein localization and cell population analysis, and reporter assays to measure transcriptional activity. Functional studies can incorporate co-immunoprecipitation to investigate protein interactions, phospho-signaling analysis for pathway activation, and apoptosis or cell proliferation assays to evaluate phenotypic consequences. Drug sensitivity studies with selective estrogen receptor modulators or degraders can be performed to test therapeutic strategies. This versatile tool aids in deciphering ESR1-mediated mechanisms in B lymphocyte biology and lymphomagenesis. For further technical details, please contact Ascent Research.
